Tag: daxibotulinumtoxina

All

Revance Reports Q4 and Full Year 2021 Financial Results; Credits Dermal Filler Sales for Growth

The company also announced progress on its DaxibotulinumtoxinA for Injection for glabellar lines and intent to launch the RHA Redensity dermal filler in the second half of 2022.

Revance Resubmits BLA to FDA for DaxibotulinumtoxinA for Injection
Aesthetic Surgeon Shares Insights on DAXI’s Potential

All

Sorry, No Posts Found

All

First U.S. Women Receive Breast Augmentation with FDA-Approved Motiva Implants

Establishment Labs Holdings Inc, a global medical technology company specializing in women’s health, announces the first U.S. breast augmentations using Motiva Implants.

Scott Hollenbeck, MD, Named ASPS President
The Plastic Surgery Foundation Names Alan Matarasso, MD, FACS, President
New Tool Prepares Breast Cancer Patients for Reconstruction Decisions

Tag: daxibotulinumtoxina

All

Revance Reports Q4 and Full Year 2021 Financial Results; Credits Dermal Filler Sales for Growth

Revance Resubmits BLA to FDA for DaxibotulinumtoxinA for Injection

Aesthetic Surgeon Shares Insights on DAXI’s Potential

All

Sorry, No Posts Found

All

First U.S. Women Receive Breast Augmentation with FDA-Approved Motiva Implants

Scott Hollenbeck, MD, Named ASPS President

The Plastic Surgery Foundation Names Alan Matarasso, MD, FACS, President

New Tool Prepares Breast Cancer Patients for Reconstruction Decisions

Sorry, No Posts Found

Plastic Surgery Practice

Our Parent Company

Key Resources

Helpful Links